Skip to content

Effect of orexin system on nicotine addiction and its neural mechanism

Effect of orexin system on nicotine addiction among smokers and its neural mechanism

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2300072930
Enrollment
Unknown
Registered
2023-06-28
Start date
2023-07-01
Completion date
Unknown
Last updated
2023-07-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

nicotine addiction

Interventions

No smoking + nicotine cue extinction group:(No smoking after 18:00 the night before) Combined with cue exposure therapy, nicotine addicts were repeatedly presented with nicotine cue picture stimuli fo
Non-smoking + neutral cue extinction group:(No smoking after 18:00 the night before) combined with cue exposure therapy, by repeatedly presenting neutral cue picture stimuli to nicotine addicts, and p
No smoking + fasting + nicotine cue extinction group:(No smoking + fasting after 18:00 the night before) Combined with cue exposure therapy, nicotine addicts are repeatedly presented with nicotine cue
No smoking + fasting + neutral cue extinction group:(No smoking + fasting after 18:00 the night before) Combined with cue exposure therapy, nicotine addicts were repeatedly presented with neutral cue
No smoking + nicotine cue extinction group:(No smoking + fasting after 18:00 the night before), after breakfast at 8:00 in the morning, combined with cue exposure therapy, by repeatedly presenting neu
Healthy control group:N/A

Sponsors

Shenzhen Kangning Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 60 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria for smokers: a. Age 18-60 years old, gender is not limited; b. Nicotine addicts, meeting the DSM-V diagnostic criteria for substance dependence, that is, smoking = 10 cigarettes per day and smoking age = 2 years; c . Be able to communicate normally with the researcher and cooperate with the researcher; d. Informed consent, voluntary participation. Inclusion criteria for healthy subjects: a. Voluntarily participate in this clinical study and sign the informed consent; b. Age 18-60 years old, gender is not limited; c. The total lifetime smoking amount before the participation in the subject is <10 and within the past year Non-smoking; d. Be able to communicate normally with the researcher and cooperate with the researcher to complete the research.

Exclusion criteria

Exclusion criteria: Exclusion criteria: 1) Those with psychotic symptoms or a family history of mental disorders; 2) Those with a history of dependence or behavior (gambling, online games) addiction other than alcohol, drugs, etc.; 3) Those who are receiving any drug treatment or Those who have taken benzodiazepines or received antipsychotic drugs within 2 weeks; 4) Those with epilepsy, craniocerebral injury history, coma history, brain organic or serious physical disease; 5) Due to obesity and smoking There is an interaction 29, and obese people with a body mass index (BMI) > 30 are excluded; 6) Those with intracranial metal implants or artificial dental implants, and those who cannot tolerate magnetic resonance examinations.

Design outcomes

Primary

MeasureTime frame
smoking craving;exhaled CO concentration;Changes in plasma orexin concentration levels;MRI imaging changes;

Countries

China

Contacts

Public ContactHuang Gengdi

Shenzhen Kangning Hospital

18600251858@163.com+86 186 0025 1858

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026